An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) demonstrate unprecedented efficacy in multiple malignancies; however, the mechanisms of sensitivity and resistance are poorly understood and predictive biomarkers are scarce. INSPIRE is a phase 2 basket study to evaluate the genomic and immune landscapes of peripheral blood and tumors following pembrolizumab treatment.

Methods

Patients with incurable, locally advanced or metastatic solid tumors that have progressed on standard therapy, or for whom no standard therapy exists or standard therapy was not deemed appropriate, received 200 mg pembrolizumab intravenously every three weeks. Blood and tissue samples were collected at baseline, during treatment, and at progression. One core biopsy was used for immunohistochemistry and the

SUBMITTER: Clouthier DL 

PROVIDER: S-EPMC6417194 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature